Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy

Background

Previous studies have suggested a link between metabolic syndrome (MetS) and prostate cancer (PCa). In the present study, we aimed to assess the association between MetS and markers of PCa aggressiveness on radical prostatectomy (RP).

微卫星不稳定性在膀胱癌复发诊断中的价值

背景与目的:评估尿脱落细胞中微卫星不稳定性(Microsatelliteinstability,MSI)在膀胱癌复发诊断中的价值及可能的临床意义。材料与方法:对60份膀胱癌术后随访尿液标本及20份正常对照标本进行微卫星不稳定性的检测。分析参数包括有无血尿、肿瘤数目、大小、WHO分级及5个微卫星位点标志物。结果:20例复发者中17例MSI阳性(85.00%),且15例为血尿标本,检测术后随访者尿脱落细胞中MSI诊断膀胱癌复发的敏感性、特异性及阳性预报值分别为85.00%、82.50%及83.33%,MSI与肿瘤分级间无明显相关性。结论:MSI可以作为膀胱癌术后随访病人尤其伴有血尿者监测肿瘤复发的良好标志物。     

A rare submucosal tumour of stomach-glomus tumour: A case report

IntroductionGlomus tumour (GT) of the stomach is a rare submucosal mesenchymal tumour. Gastric glomus tumours are clinically recognized as benign. Nevertheless, some show biological behaviour similar to that of malignant lesions and presurgical confirmation is often impossible.Presentation of caseA 32 year old female who presented with epigastric pain and was subsequently investigated for a antral tumour of the stomach and Wedge resection of tumour was done. Immunohistochemistry demonstrated strong positivity of smooth muscle actin and vimentin with low rate of mitosis studied by ki-67.DiscussionWe discuss the preoperative investigation, the diagnostic problems and the surgical treatment of the patient with gastric glomus tumour.ConclusionGlomus tumours should be considered as differential diagnosis for submucosal tumours of stomach.     

Clinical characteristics of primary intestinal NK/T cell lymphoma,nasal type: Case series and review of the literature

Background

Primary intestinal NK/T cell lymphoma is rare but aggressive and exhibits a poor prognosis. Little is known about its clinical characteristics because few studies with small sample sizes have been reported.

The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer,non-Hodgkin lymphoma

Association between HIV/AIDS and some of the cancers such as lymphomais is well known. Relative risk for developing non-Hodgkin lymphoma (NHL) increases 60–200 folds in HIV-infected individuals. Diffuse large B cell lymphoma (DLBCL), primary effusion lymphoma (PEL), Burkitt's lymphoma (BL) and Plasmablastic Lymphoma (PBL) are among the most frequent subtypes. During the last century, scientists found that the immune system could potentially detect and destroy cancer cells. Therefore, they started a new field of study, which is named immunotherapy. There are different immunotherapeutic methods, among which therapeutic antibodies, such as Brentuximabvedotin (Adcetris), Ibritumomabtiuxetan (Zevalin) and rituximab (Rituxan), used for treatment of NHLs showed promising results. In this article, we will review the immunotherapeutic option, monoclonal antibodies, for treatment of HIV-associated NHLs as well as their recent clinical status. We will also discuss the selective monoclonal antibody for each subtype of NHLs.